Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 5/20 | 0.38 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | CSF1R | P07333 | 3/20 | 0.34 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.33 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.33 |
| ▸ | PI4KA | P42356 | 1/20 | 0.33 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.33 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA7 | P43166 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | ITK | Q08881 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 5/20 | 0.32 |
| ▸ | RAB9A | P51151 | 5/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL360624 | 0.82 | IRAK4 (0.37) | PDE10ANPC1RAB9ATDP1PKM | |
| SCHEMBL14915754 | 0.80 | PDE10A (0.38) | PDE10A | |
| SCHEMBL358857 | 0.79 | MET (0.38) | PDE10A | |
| SCHEMBL367917 | 0.79 | PDE10A (0.37) | CYP3A4PDE10AKCNH2 | |
| SCHEMBL359481 | 0.78 | EGFR (0.41) | PDE10ACSF1R | |
| SCHEMBL360598 | 0.78 | PDE10A (0.38) | PDE10A | |
| SCHEMBL178094 | 0.78 | MET (0.44) | — | |
| SCHEMBL359817 | 0.78 | MET (0.40) | PDE10AALDH1A1HPGD | |
| SCHEMBL361506 | 0.78 | PDE10A (0.42) | PDE10A | |
| SCHEMBL162668 | 0.78 | MET (0.43) | PDE10ARAB9AMAPTSMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130116231-A1 | TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2013-05-09 | — | — | US | claimed |
| US-20130116231-A1 | TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2013-05-09 | — | — | US | disclosed |
| US-20130116231-A1 | TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2013-05-09 | — | — | US | disclosed |
| US-20130116231-A1 | TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2013-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130116231-A1 | TYROSINE KINASE INHIBITORS | ABL1, ERBB2, MET | CYP3A4 4244/4885PDE10A 3303/4885KCNH2 3255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.